16 results about "Hypoxic cell" patented technology

Methods to identify compounds that accelerate a transition of a cell from an acute hypoxic state to a hypoxic adaptive state include contacting a test compound with the cell in the acute hypoxic state, and detecting the transition of the cell from the acute hypoxic state to the cell in the hypoxic adaptive state and measuring the length of time of the transition; wherein the length of time of the transition is shorter in the presence of the test compound relative to the absence of the test compound, thereby identifying the compound that accelerates the transition of the cell from an acute hypoxic state to a hypoxic adaptive state. The compounds identified by the methods can be used to treat acute hypoxia and acute ischemia.

A novel strategy for wound healing involving the coating of oxygen nanobubbles with exosomes and incorporating them into a polyvinyl alcohol (PVA) / gelatin hybrid hydrogel. In this work, we not only mitigate wound hypoxia but importantly have an efficient delivery method of exosomal nanoparticles, which to date has been confounded by very low to lack of uptake by cells in hypoxia. Furthermore, the self-healing properties of the hydrogel, along with its gelatin component, aids in hemostasis, thereby benefiting acute and surgical wound healing. Additionally, the crosslinking bonds within the hydrogel facilitate the decomposition of hydrogen peroxide (H2O2), alleviating wound inflammation. The multifunctional hydrogel provides for enhanced wound healing through increased angiogenesis, enhanced exosome delivery, hypoxia mitigation, and inflammation inhibition.

The invention belongs to the technical field of biological medicines, and discloses a lactobacillus paracasei strain with an anti-hypoxia function, the name of the lactobacillus paracasei strain is 40509a, the classification name of the lactobacillus paracasei strain is lactobacillus paracasei, the preservation number of the lactobacillus paracasei strain is CGMCC No.31996, the preservation date of the lactobacillus paracasei strain is CGMCC No.31996, the preservation unit of the lactobacillus paracasei strain is China General Microbiological Culture Collection Center, and the preservation unit of the lactobacillus paracasei strain is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing. The lactobacillus paracasei 40509a can prolong the survival time of a CD-1 hypoxic mouse and inhibit the content of HIF1-alpha and PHD in serum of the hypoxic mouse so as to achieve the anti-hypoxic function, and can improve the activity of PC12 hypoxic cells and improve the expression of NSE and NGF of hypoxic cells so as to achieve the anti-hypoxic function.

The invention belongs to the technical field of medicines, and relates to a prodrug designed based on a tumor LAT1 transporter and a preparation method of the prodrug, in particular to a gemcitabine analogue prodrug taking LAT1 as a target spot and a preparation method of the gemcitabine analogue prodrug. The invention relates to a derivative shown as a total general formula and sub general formulas 1-3, and pharmaceutically acceptable salt, hydrate, solvate or prodrug structure thereof, wherein X, Y, Dug and Amino acid are defined in the specification and claims. The series of prodrugs provided by the invention can realize synchronous delivery of chemotherapeutic drugs and lactic acid transport inhibitors in tumors through LAT1 mediation. The lactic acid transport inhibitor is used for inducing apoptosis of hypoxic cells and sensitizing chemotherapeutic drugs, and the lactic acid transport inhibitor and the chemotherapeutic drugs have a synergistic effect.

The present invention belongs to the technical field of medical nanomaterials, and specifically discloses a HIFU nano-synergist and its preparation and application. The synergist includes nanoparticles loaded with banovanthraquinone and cyclic dinucleotides, and the nanoparticles are spherical nanoparticles with a metal organic framework formed by self-assembly of metal ions and banovanthraquinone cyclic dinucleotides, and the metal ions are preferably manganese ions. The present invention utilizes the response characteristics of metal coordination bonds to acid to effectively release and synergistically treat anticancer drugs banovanthraquinone and cyclic dinucleotides in tumor tissues, thereby enhancing the anti-tumor effect; banovanthraquinone can selectively act on hypoxic cells, while overcoming hypoxia resistance to kill tumor cells without harming normal tissues; manganese ions and cyclic dinucleotides are used in combination to activate the interferon gene stimulator (STING) pathway, enhance the body's innate immunity and adaptive response, thereby reversing the immunosuppression caused by the tumor microenvironment and promoting tumor immunotherapy.

The invention relates to hypoxia response therapeutic VEGFA (vascular endothelial growth factor A) mRNA (messenger Ribonucleic Acid) and application thereof. The mRNA comprises a 5'end cap, a 5 'UTR (Untranslated Region) containing a Kozak sequence, VEGFA ORF (Open Region Fragment), a 3' UTR containing an RNA (Ribonucleic Acid) binding protein HuR binding site, a RhoBAST fluorescent aptamer at the tail end of the 3 'UTR and a PolyA tail. According to the design, through a HuR hypoxia-dependent nuclear plasma transport mechanism, the stability of mRNA in hypoxic cells is improved by 2.5 times, the protein expression quantity is improved by 2 times, and proliferation of endothelial cells is remarkably promoted. Further disclosed is a VEGFA mRNA delivery system based on engineered extracellular vesicles (EVs): EVs surface modified kidney targeting peptide LTH. The system is efficiently accumulated in ischemic kidneys, VEGFA expression is remarkably enhanced, and abnormal vascular hyperplasia of external renal organs is avoided. Animal experiments prove that the survival rate of a renal ischemia-reperfusion injury model can be increased to 100% by intravenous injection of drug-loaded EVs, and the capillary density is remarkably increased 7 days after treatment. The invention is suitable for treating ischemic diseases, organ ischemia reperfusion injury or chronic wounds and the like, and has the advantages of accurate targeting, hypoxia response, high stability and safety.

The invention belongs to the technical field of biological medicines, and discloses a strain of Lactobacillus reuteri with an anti-hypoxia function, the name of the Lactobacillus reuteri is 40509a, the classification name of the Lactobacillus reuteri is Limosilbacillus reuteri, the preservation number of the Lactobacillus reuteri is CGMCC No.31996, the preservation date of the Lactobacillus reuteri is September 18, 2024, the preservation unit is China General Microbiological Culture Collection Center, the preservation number of the Lactobacillus reuteri is CGMCC No.31996, the preservation number of the Lactobacillus reuteri is CGMCC No.31996, and the preservation number of the Lactobacillus reuteri is CGMCC No.31996. The medicine is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing. The lactobacillus reuteri 40509a can prolong the survival time of a CD-1 hypoxic mouse, inhibit the content of HIF1-alpha and PHD in serum of the hypoxic mouse so as to achieve the anti-hypoxic function, and can improve the activity of PC12 hypoxic cells and improve the expression of NSE and NGF of hypoxic cells so as to achieve the anti-hypoxic function.

Provided are a hyaluronic acid compound for resisting cell hypoxia injury, a preparation method therefor, and use thereof. The hyaluronic acid compound comprises hyaluronic acid with an average molecular weight in the ten-thousands range and hyaluronic acid with an average molecular weight in the hundred-thousands range according to a volume ratio of 1:3 to 3:1. Hyaluronic acid can inhibit hypoxia-induced overactivation of HIF-1α, reduce the reactive oxygen level in hypoxic cells, and reduce the level of inflammatory factors in the supernatant of hypoxic cells, thereby alleviating hypoxia-induced cell apoptosis. Therefore, hyaluronic acid can be used in the treatment of cell hypoxia injury. Compared with hyaluronic acid of a single molecular weight, the obtained hyaluronic acid compound has a synergistic effect.

The present application relates to a kind of hypoxic fluorescent probe and its preparation method and application, belong to the field of biotechnology.The present application designs new type of hypoxic fluorescent probe, and further develops its in situ imaging application mode in the field of neurobiology, the hypoxic fluorescent probe can effectively respond to hypoxic cell, tissue, and can penetrate blood-brain barrier, release fluorescence at the place of hypoxic brain injury with azo bond broken, has the potential of clinical diagnosis neonatal hypoxic-ischemic encephalopathy.

The present invention relates to an ultrasound-responsive nanoprobe and its preparation method and application. The nanoprobe has a core-shell structure, with poly(lactic-co-glycolic acid) and a photosensitizer as the outer shell, and fluorocarbon and tirapazamine as the core. The photosensitizer is a porphyrin derivative, and the fluorocarbon is a low-boiling-point liquid fluorocarbon. Compared with the prior art, the present invention designs an ultrasound-responsive nanoprobe to sensitize hypoxia-specific anti-tumor prodrugs and improve the tumor treatment effect. Among them, the photosensitizer generates ROS under ultrasound triggering while consuming oxygen in the near-vascular oxygen-rich region, thereby deteriorating the hypoxia state of the tumor microenvironment and activating hypoxia-responsive drugs. The huge mechanical force generated by the liquid-gas phase change of the low-boiling-point liquid fluorocarbon under ultrasound triggering can destroy the tumor stromal tissue, promote the penetration depth of the hypoxia-responsive drug at the tumor site, and enable the hypoxia-responsive drug to exert an anti-tumor effect on hypoxic cells far from blood vessels.

The invention relates to the technical field of fluorescent probe preparation, in particular to a small-molecule fluorescent probe and a preparation method thereof. The structural formula of the micromolecular fluorescent probe is shown in the specification. The micromolecular fluorescent probe provided by the invention can be used for detecting hydrogen peroxide, can respond to hypoxia cells and tissues, realizes in-situ fluorescence imaging, and can effectively penetrate through a blood brain barrier.

The invention relates to a low-oxygen fluorescent probe as well as a preparation method and application thereof, and belongs to the technical field of biology. The novel hypoxia fluorescent probe is designed, the application mode of the hypoxia fluorescent probe in in-situ imaging in the field of neurobiology is further developed, the hypoxia fluorescent probe can effectively respond to hypoxia cells and tissues and can penetrate through a blood brain barrier, azo bonds are broken at the hypoxia brain injury position to release fluorescence, and the hypoxia fluorescent probe can be used for detecting hypoxia brain injury. The potential of clinically diagnosing the neonatal hypoxia ischemic encephalopathy is realized

A kind of laboratory device of long time low oxygen culture cell of flexible stability, assembly structure is simple, each block is flexibly detached in use, low oxygen gas flow rate is stable in culture, environment is sterile environment, humidity is sufficient, realize the stable culture of cell in low oxygen environment for long time.It includes gas cylinder (1), bacteria filter (3), cell low oxygen incubation chamber (5);Cell low oxygen incubation chamber includes water tank (51), metal bucket (52), glass cover (53), sealing rubber ring (54);Water tank is equipped with electric plug (514), predetermined temperature is obtained by electrification heating to water in water tank, water tank has the heat preservation cover with hole;Metal bucket, glass cover and sealing rubber ring form closed structure, the lower part of metal bucket body is immersed in the water of water tank, the upper part of metal bucket body passes through the hole of heat preservation cover and exposes water tank.

This invention provides a nitroreductase-responsive fluorescent probe, its preparation method, and its application, belonging to the field of bioanalysis and detection technology. The nitroreductase-responsive fluorescent probe of this invention has the structure shown in Formula I; this invention also provides a preparation method and application of this nitroreductase-responsive fluorescent probe. The nitroreductase-responsive fluorescent probe of this invention can react with nitroreductase and emit green fluorescence in the presence of nicotinamide adenine dinucleotide, exhibiting high specificity and sensitivity, and can realize the detection of changes in nitroreductase content in hypoxic cells and sperm.

The invention provides a nitroreductase response type fluorescent probe as well as a preparation method and application thereof, and belongs to the technical field of biological analysis and detection. The nitroreductase response type fluorescent probe disclosed by the invention has a structure as shown in a formula I; the invention also provides a preparation method and application of the nitroreductase response type fluorescent probe. The nitroreductase response type fluorescent probe disclosed by the invention can react with nitroreductase in the presence of nicotinamide adenine dinucleotide and emit green fluorescence, has high specificity and sensitivity, and can be used for detecting the content change of the nitroreductase in hypoxic cells and sperms.

The present invention aims to develop a compound and a reagent having long phosphorescence lifetimes, for use in imaging of a hypoxic cell / tissue or for use in measurement / quantification of the oxygen concentration thereof. The present invention provides a reagent for measuring oxygen concentration, comprising a compound represented by the following General Formula (I) or (II).wherein R1 and R2 each independently represent hydrogen or a C1-C6 hydrocarbon group; and X− represents a counter anion.